ReviewThe ocular surface2018
Current and emerging therapies for corneal neovascularization.
Review in The ocular surface, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
93 citing papers in PubMed, 201 citations in OpenAlex.
- Size-shrinking nanoparticles with high drug-protein payload for efficient, non-invasive treatment of corneal neovascularization.Journal of nanobiotechnology · 2026Article
- Topical application of Cas9 ribonucleoproteins inhibits corneal neovascularization in a mouse model of alkali burn injury.Gene therapy · 2026Article
- Inhibition of PRMT5 reduces angiogenesis in a corneal neovascularization model by blocking NLRP3-mediated pyroptosis.Clinical epigenetics · 2026Article
- Chiglitazar Activates PPAR-α/γ to Suppress Oxidative Stress and Angiogenesis in Corneal Neovascularization.Antioxidants (Basel, Switzerland) · 2026Article
- Sunitinib-eluting thin films for Inhibition of corneal neovascularization.Drug delivery and translational research · 2026Article
- Macrophage Extracellular Vesicles: Therapeutic Strategies for Corneal Fibrosis in Rare Diseases.Biomolecules · 2026Review
- Molecular Pathways Driving Corneal Neovascularization in Herpes Simplex Keratitis.Pathogens (Basel, Switzerland) · 2026Review
- Icariin alleviates corneal neovascularization by regulating inflammation through inhibition of macrophage polarization and the NF-κB pathway.Journal of translational medicine · 2026Article
- Spatially selective multiphoton photothermolysis guided by reflectance confocal microscopy for precise vessel closure in the mouse eye limbus.Biomedical optics express · 2026Article
- Review
- Design and PreliminaryCurrent pharmaceutical biotechnology · 2026Article
- Exosomes in corneal diseases: advances in diagnosis and therapy.Frontiers in cell and developmental biology · 2026Review
- Evaluation of a New Potential Bevacizumab Biosimilar in Corneal Neovascularization.Turkish journal of ophthalmology · 2025Article
- Role of PD-L1 in Regulatory T Cell-Mediated Suppression of Corneal Neovascularization.The American journal of pathology · 2025Article
- Current progress in research on ocular injury caused by exposure to vesicants.Progress in retinal and eye research · 2025Review
- The microenvironment of ocular surface in keratoconus: a systematic review.Eye and vision (London, England) · 2025Review
- Zeb1 Facilitates Nitrogen Mustard-Induced Corneal Epithelial Wound Healing by Maintaining Epithelial Renewability.Investigative ophthalmology & visual science · 2025Article
- miR-497 knockout aggravates alkali burn-induced corneal neovascularization via VEGFA and FGF2 pathways in mice models.International ophthalmology · 2025Article
- Effects of Dual Inhibition of VEGF-A and Angpt-2 on Angiogenesis and Lymphangiogenesis in an Alkali-Induced Corneal Injury Model.Genes to cells : devoted to molecular & cellular mechanisms · 2025Article
- Navigating the path to corneal healing success and challenges: a comprehensive overview.Eye (London, England) · 2025Review
33 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
Abstract
The cornea is unique because of its complete avascularity. Corneal neovascularization (CNV) can result from a variety of etiologies including contact lens wear; corneal infections; and ocular surface diseases due to inflammation, chemical injury, and limbal stem cell deficiency. Management is focused primarily on the etiology and pathophysiology causing the CNV and involves medical and surgical options. Because inflammation is a key factor in the pathophysiology of CNV, corticosteroids and other anti-inflammatory medications remain the mainstay of treatment. Anti-VEGF therapies are gaining popularity to prevent CNV in a number of etiologies. Surgical options including vessel occlusion and ocular surface reconstruction are other options depending on etiology and response to medical therapy. Future therapies should provide more effective treatment options for the management of CNV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.